SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CLTR COULTER PHARMACEUTICAL
An SI Board Since January 1997
Posts SubjectMarks Bans Symbol
666 17 0 CLTR
Emcee:  HARRY GIBSON Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
516 Parking the older Coulter patent: 164.195.100.11 (filed September 1993) It mPseudo Biologist-2/3/2000
515 MZ, Thanks for posting the links. Actually you'll note that I'm not pbiowa-2/3/2000
514 Before proclaiming victory for CLTR patents, did anyone read IDPH Y2B8 patents Miljenko Zuanic-2/2/2000
513 V1, Let me repeat that: <b>Message to South San Francisco, if you can gbiowa-2/2/2000
512 For anyone trying to follow the patent trail: '542 was divided from US 5,5biowa-2/2/2000
511 Biowa, IDEC, currently down 21.5 has lost almost a billion in market cap. ThatsVector1-2/2/2000
510 V1, <i>Additional bad news for IDPH</i> That's where I would biowa-2/2/2000
509 Gordon, Biowa, Peter et al, Additional bad news for IDPH. They are going to beVector1-2/2/2000
508 Looks like Tang at Deutche believes Zev is covered by the patent, and Toth at PGordon James-2/2/2000
507 Peter, <i>Also, the invention is not limited to <b>the</b> Cbiowa-2/2/2000
506 It is interesting how they went out of their way in the Example III discussion Bob L-2/2/2000
505 Peter, Might want to edit my name out of your last post. Thanks. bibiowa-2/2/2000
504 Biowa, The patent wouldn't cover Rituxan because the patent seems to only Biomaven-2/2/2000
503 Peter, <i>Rather, the invention encompasses the use of antibodies which biowa-2/2/2000
502 biowa, <i>However, the invention description calls out a very specific Biomaven-2/2/2000
501 Peter, However, the invention description calls out a very specific set of antbiowa-2/2/2000
500 Biowa, I just finished reading the patent and it looks damm broad, on its face Vector1-2/2/2000
499 Y-90 is expressly discussed in Example III as well. The "examples of the Bob L-2/2/2000
498 Well CLTR +4 and IDPH -20 as I write. May also be related to news that the ZevaBiomaven-2/2/2000
497 Russian Bear, <i>Coulter Pharmaceutical(Nasdaq:CLTR - news) and SmithKlibiowa-2/2/2000
496 Harold, That is precisely my question. I posted the news to see if someone moRussian Bear-2/2/2000
495 Does this patent encompass Idec's radiolabelled MAB?Harold Engstrom-2/2/2000
494 Wednesday February 2, 7:31 am Eastern Time Company Press Release Coulter PharRussian Bear-2/2/2000
493 biowa, <<To believe that he truly was right, I'd want to see a direcWTDEC-1/18/2000
492 Walter, OT - <i>2010</i> You're back in. On the FDA, there abiowa-1/18/2000
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News